Compare Stocks: QNTM, ICCC, ALDX, and FBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.36 -1.4%	$1.55	$1.07 ▼ $5.93	$82.04M	1.2	623,349 shs	366,921 shs
FBIO Fortress Biotech	$2.51	$2.93	$2.18 ▼ $4.53	$83.71M	1.19	299,800 shs	414,674 shs
ICCC ImmuCell	$9.95 -0.3%	$10.46	$4.52 ▼ $12.10	$90.37M	0.54	16,152 shs	10,036 shs
QNTM Quantum Biopharma	$3.66 -1.6%	$3.25	$2.07 ▼ $21.00	$23.42M	0.45	144,261 shs	95,046 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	+1.49%	-9.33%	-30.61%	-72.24%
FBIO Fortress Biotech	0.00%	-0.40%	-9.39%	-16.05%	-27.03%
ICCC ImmuCell	0.00%	+1.02%	-1.39%	+4.85%	+76.11%
QNTM Quantum Biopharma	0.00%	+14.38%	+6.40%	-3.68%	-79.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.36 -1.4%	$1.55	$1.07 ▼ $5.93	$82.04M	1.2	623,349 shs	366,921 shs
FBIO Fortress Biotech	$2.51	$2.93	$2.18 ▼ $4.53	$83.71M	1.19	299,800 shs	414,674 shs
ICCC ImmuCell	$9.95 -0.3%	$10.46	$4.52 ▼ $12.10	$90.37M	0.54	16,152 shs	10,036 shs
QNTM Quantum Biopharma	$3.66 -1.6%	$3.25	$2.07 ▼ $21.00	$23.42M	0.45	144,261 shs	95,046 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	+1.49%	-9.33%	-30.61%	-72.24%
FBIO Fortress Biotech	0.00%	-0.40%	-9.39%	-16.05%	-27.03%
ICCC ImmuCell	0.00%	+1.02%	-1.39%	+4.85%	+76.11%
QNTM Quantum Biopharma	0.00%	+14.38%	+6.40%	-3.68%	-79.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	304.41% Upside
FBIO Fortress Biotech	2.25	Hold	$17.00	577.29% Upside
ICCC ImmuCell	2.00	Hold	N/A	N/A
QNTM Quantum Biopharma	2.00	Hold	$8.00	118.58% Upside

Current Analyst Ratings Breakdown

Latest QNTM, ICCC, ALDX, and FBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/31/2026	QNTM Quantum Biopharma	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
8/21/2026	QNTM Quantum Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/17/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/14/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/8/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/2/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
FBIO Fortress Biotech	$63.26M	1.32	N/A	N/A	$2.00 per share	1.26
ICCC ImmuCell	$27.64M	3.27	$0.19 per share	51.61	$2.99 per share	3.33
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$1.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$33.85M	-$0.39	N/A	N/A	N/A	N/A	-53.14%	-34.94%	11/4/2026 (Estimated)
FBIO Fortress Biotech	$6.82M	$2.64	0.95	N/A	N/A	163.32%	83.47%	42.98%	11/16/2026 (Estimated)
ICCC ImmuCell	-$1.04M	$0.08	124.39	N/A	N/A	2.57%	2.69%	1.76%	11/12/2026 (Estimated)
QNTM Quantum Biopharma	-$26.17M	-$5.49	N/A	N/A	N/A	N/A	-582.23%	-184.20%	11/6/2026 (Estimated)

Latest QNTM, ICCC, ALDX, and FBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FBIO Fortress Biotech	-$0.20	-$0.08	+$0.12	-$0.08	$18.30 million	$18.72 million
8/13/2026	Q2 2026	ICCC ImmuCell	$0.05	$0.20	+$0.15	$0.20	$5.40 million	$7.19 million
8/13/2026	Q2 2026	QNTM Quantum Biopharma	-$0.4116	-$0.47	-$0.0584	-$0.47	N/A	N/A
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0875	-$0.09	-$0.0025	-$0.09	$31.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	4.91	4.91
FBIO Fortress Biotech	0.17	3.96	3.83
ICCC ImmuCell	0.22	4.75	2.71
QNTM Quantum Biopharma	N/A	1.20	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
FBIO Fortress Biotech	96.51%
ICCC ImmuCell	13.47%
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	11.80%
FBIO Fortress Biotech	28.50%
ICCC ImmuCell	5.70%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	6	60.33 million	53.21 million	Optionable
FBIO Fortress Biotech	78	33.35 million	23.85 million	Optionable
ICCC ImmuCell	73	9.08 million	8.56 million	Not Optionable
QNTM Quantum Biopharma	7	6.40 million	5.85 million	N/A

QNTM, ICCC, ALDX, and FBIO Headlines

Recent News About These Companies

Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target

September 17 at 2:05 PM | markets.businessinsider.com

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

September 17 at 8:00 AM | globenewswire.com

Quantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

September 15, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

September 15, 2026 | markets.businessinsider.com

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

September 15, 2026 | newsfilecorp.comN

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research

September 14, 2026 | theglobeandmail.com

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment' in MS Research

September 14, 2026 | globenewswire.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

September 11, 2026 | globenewswire.com

Quantum BioPharma Receives FDA Clearance For Lucid-MS Phase 2 Trial

September 9, 2026 | rttnews.com

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

September 9, 2026 | globenewswire.com

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

September 1, 2026 | globenewswire.com

Quantum Biopharma Provides Corporate Update

August 21, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

August 20, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

August 20, 2026 | markets.businessinsider.com

Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

August 17, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

August 17, 2026 | usatoday.com

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

August 14, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

August 13, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

August 13, 2026 | markets.businessinsider.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial

August 11, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, ICCC, ALDX, and FBIO Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$1.36 -0.02 (-1.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.42 +0.06 (+4.34%)

As of 09/18/2026 07:30 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Fortress Biotech NASDAQ:FBIO

$2.51 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.58 +0.07 (+2.79%)

As of 09/18/2026 07:54 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

ImmuCell NASDAQ:ICCC

$9.95 -0.03 (-0.30%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.90 -0.04 (-0.45%)

As of 09/18/2026 07:30 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Quantum Biopharma NASDAQ:QNTM

$3.66 -0.06 (-1.61%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.66 0.00 (0.00%)

As of 09/18/2026 07:50 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNTM, ICCC, ALDX, and FBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNTM, ICCC, ALDX, and FBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNTM, ICCC, ALDX, and FBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, ICCC, ALDX, and FBIO Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Fortress Biotech NASDAQ:FBIO

ImmuCell NASDAQ:ICCC

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNTM, ICCC, ALDX, and FBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNTM, ICCC, ALDX, and FBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNTM, ICCC, ALDX, and FBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, ICCC, ALDX, and FBIO Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Fortress Biotech NASDAQ:FBIO

ImmuCell NASDAQ:ICCC

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools